| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | — | JP Morgan | Reinstates | → Underweight | |
| 11/09/2023 | — | TD Cowen | Upgrades | Market Perform → Outperform | |
| 08/07/2023 | 1146.11% | Mizuho | → $6 | Reiterates | → Neutral |
| 05/10/2023 | 107.68% | Jefferies | $1.5 → $1 | Upgrades | Underperform → Hold |
| 03/06/2023 | 523.05% | Oppenheimer | $5 → $3 | Maintains | Perform |
| 02/27/2023 | 315.37% | Goldman Sachs | $3 → $2 | Maintains | Sell |
| 02/24/2023 | 523.05% | SVB Leerink | $5 → $3 | Maintains | Market Perform |
| 02/24/2023 | 211.53% | Jefferies | $3.2 → $1.5 | Downgrades | Hold → Underperform |
| 08/08/2022 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 05/31/2022 | 730.74% | Jefferies | $12 → $4 | Assumes | → Hold |
| 04/18/2022 | 1146.11% | Mizuho | $8 → $6 | Maintains | Neutral |
| 04/18/2022 | 523.05% | Goldman Sachs | → $3 | Downgrades | Neutral → Sell |
| 04/18/2022 | 1146.11% | SVB Leerink | $7 → $6 | Maintains | Market Perform |
| 03/16/2022 | 1146.11% | Canaccord Genuity | $25 → $6 | Maintains | Buy |
| 03/15/2022 | — | BTIG | Downgrades | Buy → Neutral | |
| 03/15/2022 | 1353.79% | SVB Leerink | $18 → $7 | Maintains | Market Perform |
| 03/15/2022 | 1561.47% | Mizuho | $35 → $8 | Downgrades | Buy → Neutral |
| 03/15/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 03/14/2022 | 1146.11% | B of A Securities | $18 → $6 | Downgrades | Neutral → Underperform |
| 03/09/2022 | 4261.37% | Oppenheimer | → $21 | Upgrades | Perform → Outperform |
| 11/08/2021 | 4053.69% | Benchmark | → $20 | Upgrades | Hold → Buy |
| 11/08/2021 | 3638.32% | SVB Leerink | $19 → $18 | Maintains | Market Perform |
| 11/05/2021 | 4261.37% | Oppenheimer | $25 → $21 | Maintains | Perform |
| 09/10/2021 | 3638.32% | B of A Securities | → $18 | Initiates Coverage On | → Neutral |
| 08/06/2021 | 3846% | SVB Leerink | $20 → $19 | Maintains | Market Perform |
| 06/28/2021 | 4884.42% | Stifel | $22 → $24 | Upgrades | Hold → Buy |
| 05/10/2021 | 4053.69% | SVB Leerink | $21 → $20 | Maintains | Market Perform |
| 04/06/2021 | 4261.37% | SVB Leerink | $20 → $21 | Maintains | Market Perform |
| 02/22/2021 | 5299.79% | Benchmark | → $26 | Downgrades | Buy → Hold |
| 01/06/2021 | 3638.32% | Stifel | → $18 | Initiates Coverage On | → Hold |
| 11/12/2020 | 4053.69% | SVB Leerink | $17 → $20 | Maintains | Market Perform |
| 08/14/2020 | 3430.63% | SVB Leerink | $18 → $17 | Maintains | Market Perform |
| 05/18/2020 | 5092.11% | Oppenheimer | $24 → $25 | Maintains | Perform |
| 05/12/2020 | 5299.79% | HC Wainwright & Co. | $32 → $26 | Reiterates | → Neutral |
| 05/08/2020 | 3638.32% | SVB Leerink | $17 → $18 | Maintains | Market Perform |
| 04/22/2020 | 5299.79% | Benchmark | → $26 | Initiates Coverage On | → Buy |
| 03/30/2020 | 4053.69% | Goldman Sachs | $18 → $20 | Upgrades | Sell → Neutral |
| 03/09/2020 | 5507.48% | JP Morgan | $28 → $27 | Maintains | Neutral |
| 03/04/2020 | 6130.53% | Barclays | → $30 | Initiates Coverage On | → Overweight |
| 02/03/2020 | 7168.95% | Mizuho | $21 → $35 | Upgrades | Neutral → Buy |
| 11/13/2019 | 5715.16% | JP Morgan | $33 → $28 | Maintains | Neutral |
| 11/12/2019 | 4884.42% | Canaccord Genuity | $20 → $24 | Maintains | Buy |
| 11/11/2019 | 6545.9% | HC Wainwright & Co. | $24 → $32 | Maintains | Neutral |
| 11/07/2019 | 7168.95% | Piper Sandler | $50 → $35 | Maintains | Overweight |
| 10/24/2019 | 3638.32% | Oppenheimer | → $18 | Initiates Coverage On | → Perform |
| 10/08/2019 | 3222.95% | Goldman Sachs | $54 → $16 | Downgrades | Buy → Sell |
| 08/09/2019 | 8415.06% | BMO Capital | $75 → $41 | Maintains | Outperform |
| 08/09/2019 | 4261.37% | Mizuho | $79 → $21 | Downgrades | Buy → Neutral |
| 08/09/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 08/09/2019 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 07/26/2019 | 16307.06% | Mizuho | $81 → $79 | Maintains | Buy |
| 02/22/2019 | 15476.32% | BMO Capital | → $75 | Initiates Coverage On | → Outperform |
| 12/13/2018 | 12776.43% | Goldman Sachs | → $62 | Initiates Coverage On | → Buy |
What is the target price for Nektar Therapeutics (NKTR)?
The latest price target for Nektar Therapeutics (NASDAQ: NKTR) was reported by JP Morgan on November 20, 2023. The analyst firm set a price target for $0.00 expecting NKTR to fall to within 12 months (a possible -100.00% downside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Nektar Therapeutics (NKTR)?
The latest analyst rating for Nektar Therapeutics (NASDAQ: NKTR) was provided by JP Morgan, and Nektar Therapeutics their underweight rating.
When is the next analyst rating going to be posted or updated for Nektar Therapeutics (NKTR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nektar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nektar Therapeutics was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
Is the Analyst Rating Nektar Therapeutics (NKTR) correct?
While ratings are subjective and will change, the latest Nektar Therapeutics (NKTR) rating was a with a price target of $0.00 to $0.00. The current price Nektar Therapeutics (NKTR) is trading at is $0.48, which is out of the analyst's predicted range.